文献速递皮肤肿瘤

欧洲日光浴床使用所致黑色素瘤首年疾病经济负担建模

Modelling first-year cost-of-illness of melanoma attributable to sunbed use in Europe.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-01-01

该研究基于系统文献检索与既定建模方法,估算欧盟及欧洲自由贸易联盟成员国黑色素瘤的疾病成本,并按购买力平价进行国际比较。

要点

  • 2012年31国约4450例黑色素瘤新发病例归因于日光浴床使用,占5.1%。
  • 患者年均加权总成本为6861至6967欧元。

核心结论

  • 本文提供了欧洲黑色素瘤成本的首个估算,并说明人工紫外线暴露在恶性黑色素瘤经济负担中的贡献。

研究设计与样本

  • 采用既定建模方法,对欧盟及欧洲自由贸易联盟所有成员国进行黑色素瘤疾病成本计算与比较。
  • 计算基于系统文献检索;对无成本信息的国家,以国内生产总值、卫生支出和国民总收入为基础外推成本。
  • 通过按各国购买力平价调整成本实现国际比较。

主要发现

  • 每患者年均加权总成本为6861至6967欧元。
  • 2012年31个纳入国家约4450例黑色素瘤新发病例由日光浴床使用诱发,占全部新发黑色素瘤的5.1%。

临床怎么用

  • 研究结果可用于向皮肤科医生和公共卫生决策者说明日光浴床使用所致黑色素瘤的经济负担。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanoma is a life-threatening disease of the skin with an increasing incidence of approximately 87 000 new cases treated per year in the European Union and the European Free Trade Association states resulting in considerable costs for the society. Since the use of sunbeds is known to be a risk factor, which can be easily avoided, costs of malignant melanoma attributable to sunbed use are modelled in the present study. METHODS: Costs-of-illness of melanoma were calculated and compared for all member states of the European Union and the European Free Trade Association states using an established modelling approach. Calculations were based on a systematic literature research. For countries with no available information on cost-of-illness the gross domestic product, health expenditures and gross national income served as a basis for extrapolation of costs. International comparison was enabled by adjusting costs by the national purchasing power parity. RESULTS: After adjusting melanoma treatment costs for the purchasing power parity, direct costs per patient vary between € 1056 in Romania and € 10 215 in Luxembourg. Costs due to morbidity range from € 102 per patient in Sweden and € 5178 in the UK resulting in total costs of € 1751-€ 12 611 per patient. Average weighted total costs per patient amount for € 6861-€ 6967 annually. In total, in 2012 approximately 4450 new cases of melanoma have been induced by sunbed use in the 31 included countries, which corresponds to 5.1% of all incident melanoma cases. National attributable melanoma costs range from € 1570 in Malta to € 11.1 million in Germany and sum up to an amount of € 32.5-€ 33.4 million for all countries. CONCLUSION: This article provides a first estimation on costs of melanoma in Europe. It illustrates the contribution of exposure to artificial ultraviolet light in the economic burden of malignant melanoma.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Krensel M, Schäfer I, Augustin M, et al. Modelling first-year cost-of-illness of melanoma attributable to sunbed use in Europe. J Eur Acad Dermatol Venereol. 2019. PMID: 30811692. doi:10.1111/jdv.15313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。